Antiviral Medication in Sexually Transmitted Diseases. Part I: HSV, HPV

Beata      Mlynarczyk-Bonikowska; Anna      Majewska; Magdalena      Malejczyk; Grazyna      Mlynarczyk; Slawomir      Majewski

doi:10.2174/13895575113136660088

Abstract

Sexually transmitted diseases (STD) are one of the most prevalent infectious diseases in the world and important cause of morbidity and mortality. Especially STDs of viral etiology are difficult to cure. In many cases the antiviral therapy can relieve the symptoms but not eliminate the virus. During the past decades, considerable progress has been made in the development of antiviral drugs. One of the oldest antiviral medications is acyclovir (ACV). It is approved to treat initial and recurrent genital herpes and as a suppressive therapy in severe recurrent genital infections as well. Drug resistance to ACV and related drugs is seen among immunocompromised hosts, including human immunodeficiency virus HIV-infected patients. Resistant infections can be managed by second-line drugs - foscarnet or cidofovir- but they are more toxic than ACV. In case of HPV there is not known specific target for the medication and that is why the substances used in human papilloma virus HPV infection therapy are either antimitotics or immunomodulators. The Part I review focuses on mechanisms of actions and mechanisms of resistance to antiviral agents used in a treatment of the genital herpes and genital HPV infection. In Part II we will show the therapeutic options in other sexually transmitted infections: hepatitis B, C and HIV

Keywords: Acyclovir, antimitotics, cidofovir, katechins, imiquimod, podophyllotoxin, immunomodulators, antimicrobial resistance, sexually transmitted diseases.